We examined the feasibility of high-level production of recombinant human prolactin, a multifunctional protein hormone, in insect cells using a baculovirus expression system. The human prolactin cDNA with and without the secretory signal sequence was cloned into pFastBac1 baculovirus vector under the control of polyhedrin promoter. Prolactin was produced upon infection of either Sf9 or High-Five cells with the recombinant baculovirus containing the human prolactin cDNA. The production of recombinant prolactin varied from 20 to 40 mg/L of monolayer culture, depending on the cell types. The prolactin polypeptide with its own secretory signal was secreted into the medium. N-terminal amino acid sequence analysis of the recombinant polypeptide purified from the culture medium indicated that the protein was processed similar to human pituitary prolactin. Carbohydrate analysis of the purified protein indicated that a fraction of the recombinant prolactin made in insect cells appeared to be glycosylated. Also, both secreted and nonsecreted forms of the recombinant prolactin in insect cells were biologically equivalent to the native human prolactin (pituitary derived) in the Nb2 lymphoma cell proliferation assay.
Prolactin (PRL)
2 is one of the most versatile hormones of the pituitary gland in terms of biological actions. It is involved in more physiological processes than all other pituitary hormones combined. Among these are the regulation of mammary gland development, initiation and maintenance of lactation, immune modulation, osmoregulation, and behavioral modification (1, 2) . Human prolactin is synthesized as a precursor polypeptide (preprolactin) of 227 amino acids in length. The first 28 residues constituting the signal peptide sequence are cleaved during processing in the secretory pathway and generate 199 amino acid long mature prolactin with a molecular mass of 23 kDa (3, 4) . In most mammalian species, the mature hormone consists of 197-199 amino acids, with variable sequence homology among the species. PRL was originally identified in pituitary extract; however, research in recent years has shown the presence of PRL and PRL-like molecules in the placenta, brain, and gut and in the tissues of immune system as well (4) .
PRL has also been detected in milk of the cow, goat, pig, sheep, rat, and primate (5) . Although PRL plays an essential role in the initiation and maintenance of lactation in the mother, the results of several animal studies lend support to a role of milk-borne PRL in the development of neuroendocrine, reproductive, and immune function in the neonate (5, 6) . In breast-fed human infants, prolactin activity has been detected in serum when no endogenous hPRL production takes place. The possibility that PRL may play an important role in the development of human neonate is suggested from reports that serum PRL levels are positively correlated to the stage of development (gestational age at birth) and that serum prolactin levels below 33 ng/ml are associated with poor clinical outcome of the infant (5) . The transport of milk prolactin into the infant's circulation is believed to occur through receptors that are abundantly expressed by the mucosal cells along the gut. Gut receptors have high affinity for prolactin and increase in number with age in the various species tested (7) . How pituitary PRL is able to serve as a key lactogenic agent in the mother, whereas milk-borne PRL seemingly influences the development of unrelated organ systems in the neonate, is poorly under-stood, but may in part be due to modification of prolactin structure and function as it is transferred into milk. In suckling neonatal animals, it has been demonstrated that milk-borne prolactin is responsible for the proliferation and differentiation of T-cells and B-cells (5, 6) . The role of prolactin as an immunomodulator has been demonstrated both in vitro and in vivo (5, 6) . A survey of the literature and data indicate that prolactin may be of potential clinical use after bone marrow transplantation to promote hematopoietic and immune recovery (8) . Prolactin promotes proliferation of murine B-cell hybridomas and has been shown to act as an antagonist of TGF-␤, an immunosuppressive cytokine (9) . These findings provide an additional rationale for using recombinant PRL clinically in immunosuppressed patients in certain disease settings such as AIDS and cancer, where overexpression of TGF-␤ has been implicated in disease development and progression (9) .
Recent reports indicate that PRL exhibits microheterogeneity (4, 5, 10) , which may account for these varied biological activities. Posttranslational modifications of prolactin include glycosylation, phosphorylation, oligomerization, and proteolytic cleavage. The consistent presence of these modified forms of prolactin in human milk and serum suggests that they might have physiological relevance. Although the physiological role of glycosylated and phosphorylated variants is unknown, the N-terminal fragments of rat and human prolactin have been shown to have antiangiogenic activities as demonstrated both in vitro and in vivo (11) . The lack of purified forms from either human pituitary or human milk has hindered studies to delineate the functional differences among different prolactin variants. To overcome this problem, we attempted to produce recombinant human prolactin in large quantities in eukaryotic cells. A major advantage of recombinant hPRL is its lack of contamination with other related hormones (e.g., growth hormone) that might interfere in functional assays. To date, human prolactin has been produced in bacteria (12, 13) as well as in mammalian cells (14) . Although the posttranslational modifications have been observed with PRL produced in mouse C127 cells (14) , the limitation of the stable transfection system is that the amount of protein produced is not high enough to obtain purified forms in large quantities (14) . Also, the commercial use of recombinant protein purified from mammalian cells has regulatory safety concerns since most of the mammalian cell lines are transformed with pathogenic or infectious viruses. We chose the baculovirus expression system since this system produces foreign proteins in large quantity and, in most cases, the recombinant proteins are processed and modified in a manner similar to that of their authentic counterparts (15, 16) . Moreover, baculoviruses have a restricted host range, limited to specific invertebrate species. These viruses are safer to work with since they are noninfectious to vertebrates. Most of the susceptible insect cell lines are not transformed with pathogenic or infectious viruses and can be cultured under minimal containment conditions. Here, we report the successful production of large amounts of biologically active human prolactin in insect cells. Further biochemical analysis of the purified protein indicates that the recombinant human prolactin produced in these cells is processed and modified in a manner similar to that of its native counterpart.
MATERIALS AND METHODS

Subcloning of Human Prolactin cDNA in Baculovirus
Transfer Vector pFastBac1
The human prolactin (hPRL) cDNA in a pBR322 vector was generously provided by Dr. John Kopchik, Ohio University, Athens, OH. To amplify a hPRL cDNA lacking a secretory signal sequence, the forward primer RO 468 (5Ј-ATATCGCGGATCCATGTTGC-CCATCTGTCCCGGC-3Ј) was used. This primer also contained a BamHI site and a start codon 5Ј of the hybridizing sequence. The reverse primer RO 469 (5Ј-ATATCCGCTCGAGTTAGCAGTTGTTGTTGTGG-3Ј) had an XhoI site after the stop codon. To amplify the hPRL cDNA encoding a signal sequence, the forward primer RO 510 (5Ј-ATATCGCGGATCCATGAACAT-CAAAGGATCGCC-3Ј), which contained a BamHI site upstream of the ATG, was used. RO 469 was used as the reverse primer. DNA fragments were amplified by using PCR. The polymerase chain reaction in a final volume of 100 l was carried out for 25 cycles in temperature conditions of 30 s at 94°C, 30 s at 45°C, and 30 s at 72°C. The PCR-amplified products were gel purified, digested with BamHI and XhoI, and ligated onto pFastBac1 baculovirus transfer vector (Life Technologies, Gaithersburg, MD) restricted with BamHI and XhoI. This vector contains a mini-Tn7 element, an E. coli origin of replication, and an ampicillin marker. The mini-Tn7 contains an expression cassette consisting of gentamycin resistance marker, polyhedrin promoter, a multicloning site, and an SV40 PolyA signal inserted between the left and right arms of Tn7. Initial transformation and screening were done in XL1 blue (Invitrogen, Carlsbad, CA), and the positive clones were confirmed by dideoxy sequencing and used for transformation of E. coli DH10Bac.
Cell Culture and Virus
The Bac-To-Bac baculovirus (Life Technologies) is a derivative of Autographa californica nuclear polyhedrosis virus (AcMNPV). The recombinant virus was propagated in a monolayer culture of Spodoptera frugiperda cells, Sf9. Serum free medium adapted Sf9 cells (Life Technologies) were grown in a monolayer culture at 27°C in serum-free medium, Sf-900 II SFM (Life Technologies) in the presence of a final concentration of 0.5ϫ penicillin-streptomycin-glutamine (PSG (100ϫ) stock purchased from Life Technologies). HighFive cells adapted in serum-free medium were purchased from Invitrogen and grown in a monolayer culture at 27°C in High-Five serum-free medium according to the manufacturer's protocol (Invitrogen).
Generation of Recombinant Baculovirus
Generation of recombinant baculovirus expressing human prolactin in Sf9 cells was carried out by using the Bac-To-Bac baculovirus expression kit purchased from Life Technologies. DNA of the recombinant pFasBac1 transfer vector containing cDNA corresponding to either human preprolactin or the mature prolactin sequence was introduced into E. coli DH10Bac for the transposition of the prolactin cDNAs into baculovirus genomic DNA (bacmid) according to the manufacturer's protocol. Colonies containing recombinant bacmids were identified by disruption of the lacZ␣ gene, and the white colonies were picked for recombinant bacmid DNA isolation. DNA was isolated using a Qiagen plasmid isolation kit (Qiagen Inc., Valencia, CA) specific for DNA over 135 kb long. The recombinant bacmid DNAs were analyzed on a 0.6% agarose gel followed by PCR analysis using pUC/M13 forward and reverse primers to confirm the presence as well as correct insert size of transposed prolactin cDNA within the bacmid. The recombinant bacmid DNA was then used to transfect Sf9 cells which were grown in serum-free medium. At a density of 1 ϫ 10 6 cells per 35-mm well, the cells were transfected with the bacmid DNA using Cellfectin reagent according to the manufacturer's protocol (Life Technologies). The recombinant virus was harvested at 72 h posttransfection. Plaque assays were performed on the supernatants to determine the titer of recovered recombinant virion particles, and each recombinant viral stock was made for expression studies. Plaque assay and propagation of virus were carried out according to the manual provided with the kit.
Production of Recombinant Protein
To analyze the production of prolactin, Sf9 or HighFive cells were grown in 75-mm tissue culture flasks till 70 -80% confluency. The cells were infected with recombinant virus at different multiplicities of infection (moi) and the infection was carried out at 27°C for 48 h. To examine the intracellular production, cytoplasmic extract was prepared from the infected cells as described previously (17) . Cells were washed with phosphate-buffered saline and suspended in 0.5 ml of homogenization buffer containing 10 mM Tris-HCl (pH 8.0) and 25 mM NaCl. Cells were disrupted with a Dounce homogenizer and the lysate was centrifuged at 10,000g at 4°C for 5 min. The supernatant was analyzed for the presence of prolactin. To examine the extracellular production, the culture medium was collected 48 h postinfection followed by centrifugation at 10,000g at 4°C for 5 min and the supernatant was collected and analyzed for the presence of secreted prolactin.
Western Blot Analysis
For Western blot analysis, approximately 2 g of cytoplasmic extract or 5 l of culture medium supernatant was electrophoresed on a 14% precast polyacrylamide gel (Novex, San Diego, CA), and the resolved protein was transferred onto an Immobilon-P membrane (Millipore, Bedford, MA) according to the manufacturer's protocol. After blocking with BSA, the membrane was probed with anti-human prolactin monoclonal antibody (Biomeda Corp., Foster City, CA) followed by peroxidase-linked goat anti-mouse IgG. Prolactin was visualized by ECL (Amersham Pharmacia Biotech Inc., Piscataway, NJ) according to the manufacturer's protocol.
Immunoassay
The amount of prolactin present in the cell extract or in the culture medium was determined by IMx immunoassay according to the manufacturer's protocol (Abbott Laboratories, Chicago, IL). The IMx system is a fully automated immunoassay analyzer designed to run assays using enzyme immunoassay and fluorescence polarization immunoassay technologies. The IMx prolactin assay is based on microparticle enzyme immunoassay technology, which makes use of an "antibody-antigen-antibody" complex and the generation of a fluorescent reaction product (4-methylumbelliferyl) to determine part per billion (ppb) levels of prolactin in a sample. The mock-infected cell extract and the culture medium were used as controls.
Prolactin Bioassay
The Nb2 rat lymphoma cell line (18) , which is dependent on prolactin for growth, was used to assay bioactivity of the recombinant human prolactin according to the method described previously (12) . Increasing amounts of recombinant prolactin (as diluted cell extract or culture medium) were added to Nb2 cells plated in multiwell Falcon plates at 2 ϫ 10 5 cells per well. Each sample was assayed in quadruplicate and cell cultures with mock extract or mock culture medium were used as controls. After 72-h incubation with prolactin, cell numbers were determined with a Coulter counter (12) .
Since rat Nb2 cell proliferation assay depends on the binding of human prolactin with rat receptors, a new bioassay of human prolactin has been developed in a homologous system (19) . The new bioassay involves the use of human embryonic kidney cells 293 stably expressing the human PRLR cDNA and the lactogenic hormone responsive element (LHRE) luciferase reporter (20) . LHRE is the DNA binding element of the signal transducer and transactivator Stat5 (21) , one of the signaling proteins activated by dimerized PRLR (22) . Thus, the expression of luciferase in these doubly transfected cells (HL) depends exclusively on the human prolactin present in the culture medium. Luciferase assays were performed as described previously (19) . Increasing amounts of recombinant prolactin were added to HL cells plated in multiwell plates at 5 ϫ 10 4 cells per well. Each sample was assayed in duplicate. After 18 -24 h of stimulation, cells were harvested and lysed in 50 l of lysis buffer. Luciferase activity of each experiment was counted in 10 -20 l of cell lysates for 10 s. The difference between duplicates never exceeded 15% of relative light unit (RLU) values.
Protein Purification
The secreted recombinant human prolactin in the culture medium from either mouse L-cells (positive control) or Sf9 cells was first dialyzed against buffer containing 10 mM Tris-HCl (pH 8.0) and 25 mM NaCl. After extensive dialysis (2-3 changes) at 4°C, the medium was concentrated two-to threefold by an Amicon filtration device using a 10-kDa cutoff membrane. The concentrated, dialyzed material was then applied to a Mono Q FPLC column (Amersham Pharmacia Biotech Inc.). The column was equilibrated with a buffer containing 10 mM Tris-HCl (pH 8.0) and 25 mM NaCl. After loading the protein, the column was washed with the same buffer and eluted with a gradient of 25-300 mM NaCl in Tris-HCl (pH 8.0). One-milliliter fractions were collected and analyzed on a 14% SDS-polyacrylamide gel stained with Coomassie blue.
N-Terminal Sequencing and Carbohydrate Analysis
Purified prolactin was electrophoresed on a 14% SDS-polyacrylamide gel at constant power. The protein bands were transferred to the polyvinylidene difluoride (PVDF) membrane as described elsewhere (23) , excised after staining with Coomassie blue R-250, and subjected to N-terminal amino acid sequencing in a Procise sequencing system, Applied Biosystem Model 494.
For carbohydrate analysis, the purified protein was transferred to the PVDF membrane as described above. The protein bands were excised and subjected to monosaccharide analysis of glycoconjugates by anion exchange chromatography with pulsed amperometric detection. This analysis was performed on a Dionex BioLC according to the methods described earlier (24) .
Reagents
All molecular biology reagents were purchased from Boehringer Mannheim (Indianapolis, IN). Reagents for protein purification and analysis were purchased from VWR Scientific and Bio-Rad (Richmond, CA). Purified pituitary human prolactin was purchased from Biodesign (Kennebunk, ME). The culture medium of mouse L-cells (stably expressing human prolactin cDNA with secretory signal sequence) containing recombinant human prolactin was received from the laboratory of Dr. John Kopchick, Ohio University, Athens, OH.
RESULTS
Production of Human Prolactin in Insect Cells
The human prolactin cDNA was cloned into the baculovirus vector pFastBac1 (Fig. 1) as detailed under Materials and Methods. The cDNA either corresponding to 227 amino acid long preprolactin (for extracellular expression) or corresponding to 199 amino acid long mature prolactin (for intracellular expression) was used for subcloning into baculovirus transfer vector, pFastBac1. The recombinant plasmid was then introduced into E. coli DH10Bac for the transposition of prolactin cDNAs into baculovirus genomic DNA (bacmid). To generate recombinant baculovirus, the recombinant bacmid DNA was used to transfect Sf9 insect cells and the recombinant virus was harvested 72 h posttransfection.
To analyze the production of prolactin, the Sf9 cell monolayer was infected with recombinant virus at different moi. At 48 h postinfection, the medium was collected and saved, and the cytoplasmic extract was prepared. The cell extract and the culture fluid were electrophoresed in a 14% polyacrylamide gel, and the protein bands were electroblotted onto Immobilon-P membrane. The blot was probed with monoclonal antihuman prolactin antibody and developed with ECL reagent. The results shown in Fig. 2A indicate that the expression of prolactin in the case of Sf9(hPRL) (prolactin cDNA without secretory signal sequence) is exclusively intracellular and almost no prolactin polypeptide was detected in the culture medium as expected (data not shown). In the case of Sf9(hsPRL) (prolactin cDNA with secretory signal), a majority of the prolactin was recovered in the culture medium, indicating that preprolactin was processed in insect cells and the mature prolactin was secreted into the medium (Fig. 2B) . The secreted prolactin from insect cells was comigrated with native prolactin in the polyacrylamide gel (Fig.  2B) .
To quantify the production levels, either Sf9 or HighFive cells were infected with the recombinant virus at 5 moi for 48 h postinfection. No significant increase in expression level was achieved in Sf9 cells at 48 h postinfection by increasing the moi from 5 to 10 (Fig.  2) . To measure the intracellular production levels, the cells were lysed and cytoplasmic extract was made and subsequently used in immunoassay. To measure the amount of secreted prolactin, the culture medium was collected and used directly in immunoassay. The intracellular production appeared to be twofold higher than the extracellular production (Table 1) . Also, High-Five cells are a better host than Sf9 in terms of prolactin production. In these cells, the intracellular production levels obtained were around 35-40 mg/L of culture while the amount of secreted prolactin varied from 18 to 20 mg/L of culture medium ( Table 1) .
Bioactivity of Recombinant Prolactin Expressed in Insect Cells
To determine whether the human prolactin expressed in insect cells was biologically active, an in vitro cell proliferation assay was performed according to Tanaka et al. (25) . However, in this assay, human prolactin interacts with the heterologous rat receptors and stimulates the Nb2 cell proliferation. To test the bioactivity of human prolactin in a homologous system, we have used a bioassay developed by generating human embryonic kidney fibroblast 293 cells stably expressing the human prolactin receptor cDNA and a prolactin-responsive (LHRE) luciferase reporter gene (19) . The luciferase induction is dependent on the amount of prolactin added to the culture medium. Increasing amounts of culture medium containing secreted prolactin or cytoplasmic extract (in the case of intracellular expression) were added to either Nb2 or 293 (LHRE) cells in tissue culture plates. For Nb2 cell proliferation assay, the cell numbers were counted 72 h after addition of prolactin, while for LHRE induction assay, luciferase activity was measured in the cell lysate prepared from 293 (LHRE) cells after 18 -24 h of stimulation with recombinant hormone. The stimulation of Nb2 cell proliferation or induction of LHRE by recombinant human prolactin produced in insect cells is illustrated in Fig. 3 . A high level of similarity (a strict parallelism) between the dose-response curves of insect cell derived prolactin and native or mammalian cell produced prolactin indicates that the recombinant human prolactin produced by insect cells is as active as its authentic counterpart.
Purification and Characterization of Recombinant Prolactin from Insect Cells
The medium from a 100-ml culture of Sf9 cells infected with the recombinant baculovirus (containing prolactin cDNA with secretory signal sequence) at a moi of 5 plaque-forming units (pfu) per cell was collected 48 h postinfection. The secreted prolactin present in the culture medium was applied on a Mono Q FPLC column as described under Materials and Methods. The prolactin was eluted from the column by a linear 25-300 mM NaCl gradient and the fractions were subjected to 14% SDS-PAGE analysis. The resolved protein gel was stained with Coomassie blue (Fig. 4A) . The prolactin protein from the Mono Q column eluted in a distinct peak at approximately 150 mM NaCl. The purified prolactin (pooled peak fractions) derived from insect cells comigrated with native prolactin in the SDS-polyacrylamide gel and appeared to be more than 90% pure (Fig. 4A) .
To confirm that during translation and membrane translocation in insect cells the secretory signal at the N-terminal end of the recombinant protein was cleaved properly, we carried out N-terminal sequence analysis of the recombinant prolactin purified from insect cell culture medium. To compare with the N-terminal se- quence of human prolactin produced in mammalian cells, we purified the secreted prolactin from the culture medium of mouse L-cells (stably expressed human prolactin) by Mono Q column chromatography. The purified protein samples were electrophoresed in a 14% SDS-polyacrylamide gel and transferred to the PVDF membrane. The protein bands were excised and subjected to N-terminal sequencing. The results shown in Fig. 4B indicate that in insect cells the human prolactin with its own secretory signal was processed in a manner similar to that which takes place in mammalian cells.
It can be noticed in Fig. 4A that the native or recombinant prolactin band appeared as a doublet in the 14% SDS-polyacrylamide gel. This could be due to posttranslationally modified forms present in the purified prolactin preparation. Since human prolactin produced in mammalian cells is known to exist as the glycosylated form (14) , we were interested in determining whether human prolactin produced in insect cells is also glycosylated. The carbohydrate composition of glycosylated prolactin (if any) present in the purified fraction from insect cells was analyzed. In parallel, the purified prolactin fraction from mouse L-cells was also analyzed for comparison. The monosaccharide analysis of the prolactin fractions purified from the Mono Q column is presented in Table 2 . The results indicate that the recombinant human prolactin produced in insect cells exists as a glycosylated form. The monosaccharide composition of the glycosylated prolactin derived from insect cells appears to be similar to that derived from mouse L-cells, albeit to a lesser extent. In contrast to earlier reports (14), we could not detect any fucose moiety in our analysis, even in the mammalian cell expressed prolactin fraction.
DISCUSSION
Prolactin is one of the most versatile hormones of the pituitary in terms of its biological actions; how a single molecule exerts different responses in an organism is not known. Recent findings on structural polymorphism of prolactin lend credence to the hypothesis that the molecular heterogeneity of prolactin is one of the mechanisms for creating diversity in the biological actions of this hormone. The prolactin used in the structural and biochemical analyses was primarily purified from different sources such as pituitary, placenta, milk, and other organs. Since the purification of prolactin from these sources is cumbersome, the lack of purified forms has hindered studies to delineate functional differences between these molecules. On the other hand, a major advantage of producing recombinant prolactin is its lack of contamination with other pituitary hormones (e.g., GH and CS) that may interfere in immunoassays as well as functional assays. Moreover, the expression of different forms of prolactin can be regulated by genetic manipulation, thereby underscoring the utility of recombinant prolactin in studying the structure-function relationship of this important hormone. So far, the recombinant expression of human prolactin has been achieved in E. coli (12, 13) and in mammalian cells (14) . Although the posttranslational modifications have been observed with prolactin expressed in mouse C127 cells (14) , the limitation of the stable transfection system is that the amount of protein produced (5-10 mg/L of culture) is not sufficient for purification in large quantities. Also, there are regulatory safety issues for the commercial use of recombinant proteins purified from mammalian cells. Moreover, genetic manipulation is cumbersome as well as time-consuming for stable expression systems. To overcome these disadvantages, we chose the baculovirus expression system (BEVS) since this expression system produces foreign proteins in large quantity and, in most cases, the recombinant proteins are processed and modified in a manner similar to that of their authentic counterparts (15, 16) . Here, we have described a protocol for the synthesis of biologically active recombinant human prolactin in large amounts in insect cells using the baculovirus expression system and subsequent purification and characterization. The level of recombinant prolactin produced by insect cells was greater than that obtained in mammalian cells and found to be as active as its native counterpart (Fig. 3) . The quantitative analysis presented in Table 1 clearly indicates that the intracellular production is more efficient (ϳ40 mg/L of culture) than extracellular production (ϳ20 mg/L of culture medium). To rule out the possibility that in the case of extracellular production 50% prolactin remained within the cells, we analyzed the cell pellet and found that only 15-20% prolactin was retained within the cells (data not shown). Thus, the extracellular expression level was 30 -40% lower than the level when the same protein was produced intracellularly. However, the major advantage of extracellular production is the ease of purification of the secreted protein from the serum-free culture medium. It can be noticed in Fig. 4A that a significant purification can be achieved by a single Mono Q column chromatography of the culture medium. Recently, an affinity purification of human prolactin from pituitary extract has been developed using a heparin column (26) . Therefore, this single-step heparin affinity chromatography would be useful to purify prolactin from insect cell extract. It is important to mention that our quantification of the production level of recombinant prolactin was based on a monolayer culture. The use of an insect cell suspension culture in a bioreactor generally facilitates the production level of a foreign protein compared to that in a monolayer culture (27) . Therefore, using a suspension culture in a bioreactor, the production level of prolactin could be increased severalfold over the level reported here using a monolayer culture. The interesting observation is that the recombinant human prolactin, when expressed in insect cells with its own secretory signal, was processed and secreted into the culture medium (Fig. 2) . These results obviously support the contention that prolactin produced in insect cells undergoes processing and modifications similar to those found in mammalian cells or in human pituitary. Moreover, the results of carbohydrate analysis indicate that a portion of the recombinant human prolactin produced in insect cells exists as a glycosylated form (Table 2 ). Based on the results presented in Table 2 , the molar ratio of monosaccharides in a single chain appears to be mannose 1 :GlcNAc 2 :galactose 2 and the predicted amount of glycosylated form present in the Mono Q fraction of prolactin purified from the insect cells seems to be around 7%, assuming that a monomer of mannose is present in a single carbohydrate chain. However, in Fig. 4A , it can be noticed that the slower migrating band in the doublet is more intense than the faster one. This slower migrating band could be a mixture of various modified forms of prolactin, e.g., glycosylated and phosphorylated, or the faster migrating band could be a C-terminal truncated prolactin (since the N-terminal sequence is intact as determined by sequence analysis). In the pituitary gland, glycosylated prolactin comprises a variable percentage of the total prolactin, ranging from 5 to 40% in humans (4) . The ratio of nonglycosylated to glycosylated prolactin in human serum varies according to certain physiological states and potential disease states (14). Thus, high-level production of bioactive human prolactin in insect cells will give us an opportunity to study its structure-function relationship.
The baculovirus expression system described here can be used for large-scale production of bioactive human prolactin variants, and the availability of these reagents would provide a means to dissect the role of prolactin variants in modulating the immune system and would serve to promote the study of the physiological relevance of different variants, particularly prolactin fragments. In this regard, it is important to mention that the members of the human prolactin/growth hormone family; i.e., human prolactin, human growth hormone, and human placental lactogen, are angiogenic whereas their respective 16-kDa N-terminal fragments are antiangiogenic (11) . The opposite actions are regulated in part via activation or inhibition of the mitogen-activated protein kinase signaling pathway. The concept that a single molecule encodes both angiogenic and antiangiogenic peptides represents an efficient model for regulating the balance of positive and negative factors controlling angiogenesis. This hypothesis has potential physiological importance for the control of the vascular connection between the fetal and maternal circulations in the placenta, where human prolactin, placental lactogen, and growth hormone variants are expressed. Thus, the 16-kDa variant represents a potential therapeutic agent for the treatment of cancer or other diseases whose etiology necessarily involves angiogenesis.
